Showing results (11-20 of 30) with videos related to

Sort By:
Pageof 3
Clinical Colorectal Cancer|November 19, 2016
Prognostic Impact of Primary Tumor Location on Clinical Outcomes of Metastatic Colorectal Cancer Treated With Cetuximab Plus Oxaliplatin-Based Chemotherapy: A Subgroup Analysis of the JACCRO CC-05/06 TrialsYu Sunakawa, Wataru Ichikawa, Akihito Tsuji, et al.
Molecular Diagnosis & Therapy|September 1, 2025
Circulating Tumor DNA Profiling Reveals Genomic Evolution in Recurrent Gastric or Gastroesophageal Junction CancerRyohei Kawabata, Hiroyuki Takeda, Atsushi Ishiguro, et al.
Cancer Chemotherapy and Pharmacology|June 26, 2016
Panitumumab in combination with irinotecan plus S-1 (IRIS) as second-line therapy for metastatic colorectal cancerToshi Takaoka, Tetsuo Kimura, Rai Shimoyama, et al.
Clinical Colorectal Cancer|January 19, 2016
Uracil-Tegafur and Oral Leucovorin Combined With Bevacizumab in Elderly Patients (Aged ≥ 75 Years) With Metastatic Colorectal Cancer: A Multicenter, Phase II Trial (Joint Study of Bevacizumab, Oral Leucovorin, and Uracil-Tegafur in Elderly Patients [J-BLUE] Study)Tomohiro Nishina, Toshikazu Moriwaki, Mitsuo Shimada, et al.
Clinical Colorectal Cancer|September 17, 2018
Immune-related Genes to Dominate Neutrophil-lymphocyte Ratio (NLR) Associated With Survival of Cetuximab Treatment in Metastatic Colorectal CancerYu Sunakawa, Dongyun Yang, Shu Cao, et al.
European Journal of Cancer (Oxford, England : 1990)|March 8, 2020
Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric/gastroesophageal junction cancer: Cohort 1 data from the KEYNOTE-659 phase IIb studyAkihito Kawazoe, Kensei Yamaguchi, Hisateru Yasui, et al.
Japanese Journal of Clinical Oncology|April 26, 2022
Impact of chronological age on efficacy and safety of fluoropyrimidine plus bevacizumab in older non-frail patients with metastatic colorectal cancer: a combined analysis of individual data from two phase II studies of patients aged >75 yearsToshikazu Moriwaki, Tomohiro Nishina, Yoshinori Sakai, et al.
Targeted Oncology|April 15, 2023
A Multicenter, Phase II Trial of Schedule Modification for Nab-Paclitaxel in Combination with Ramucirumab for Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer: The B-RAX Trial (JACCRO GC-09)Ryohei Kawabata, Naoki Izawa, Takahisa Suzuki, et al.
British Journal of Cancer|September 1, 2020
Phase 2 study of irinotecan plus cetuximab rechallenge as third-line treatment in KRAS wild-type metastatic colorectal cancer: JACCRO CC-08Toshiki Masuishi, Akihito Tsuji, Masahito Kotaka, et al.
Molecular Cancer Therapeutics|October 3, 2018
Tumor Sidedness and Enriched Gene Groups for Efficacy of First-line Cetuximab Treatment in Metastatic Colorectal CancerYu Sunakawa, Kaoru Mogushi, Heinz-Josef Lenz, et al.
Pageof 3